title: Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation.
abstract: Patients receiving vitamin K-antagonists are monitored by regular assessment of the International Normalized Ratio (INR). There are two popular methods for therapeutic control of anticoagulation in patient groups: 1) Time in Therapeutic Range (TTR) assessed by linear interpolation of successive INR measurements; 2) the cross-sectional proportion (CSP) of all patients' last INRs within range. The purpose of the present study is to compare the two methods using data from 53 Dutch Thrombosis Centres and to develop a semi-quantitative model for TTR based on different types of INR change. Different groups of around 400,000 patients in four consecutive years were evaluated: patients in the induction phase, short-term, long-term, low-target range, high-target range, receiving either acenocoumarol or phenprocoumon, and performing self-management. Each Centre provided TTR and CSP results for each patient group. TTR and CSP were compared using the Wilcoxon signed-rank test. Separately, we analysed the relationship between consecutive INR results regarding in or out of range and their frequency of occurrence in patients of two different cohorts. Good correlation was observed between TTR and CSP (correlation coefficient 0.694-0.950 in low-target range). In long-term acenocoumarol patients (low-target range) the median TTR was significantly higher than CSP (80.0 % and 78.7 %, respectively; p<0.001). In long-term phenprocoumon patients (low-target range) there was no significant difference between median TTR (83.0 %) and median CSP (82.6 %). In conclusion, the correlation between TTR assessed by linear interpolation and CSP was good. TTR assessed by linear interpolation was higher than CSP in patients on acenocoumarol.
authors.affiliation: A. M. H. P. van den Besselaar, Department of Thrombosis and Hemostasis,, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands, Tel.: +31 71 5261894, Fax: +31 71 5266868, E-mail: a.m.h.p.van_den_besselaar@lumc.nl.
authors.forename: A M H P
authors.initials: AM
authors.lastname: van den Besselaar
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Biedermann
authors.forename: Felix J M
authors.initials: FJ
authors.lastname: van der Meer
authors.forename: Henk J
authors.initials: HJ
authors.lastname: Adriaansen
authors.forename: Frank W G
authors.initials: FW
authors.lastname: Leebeek
authors.forename: Marieke J H A
authors.initials: MJ
authors.lastname: Kruip
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D006801:Humans; D019934:International Normalized Ratio; D008962:Models, Theoretical; D009426:Netherlands; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K
keywords: Vitamin K antagonist; therapeutic control; time in therapeutic range